Symbol not found

:CYTR  
0.00
0.00 (0.00%)
Products

CytRx Highlights Orphazyme's Receipt Of FDA Acceptance & Priority Review Of NDA For Arimoclomol

Published: 09/17/2020 13:37 GMT
(CYTR) - Cytrx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of Its New Drug Application for Arimoclomol for Niemann-pick Disease Type C.